Gyre Therapeutics Reports 20% Revenue Growth to $30.6 Million in Q3 2025

Gyre Therapeutics, Inc. reported a significant increase in financial performance for the third quarter of 2025, with revenues reaching $30.6 million, a 20% increase from $25.5 million in the same period last year. For the nine months ending September 30, 2025, total revenues were $79.4 million, up from $77.9 million in 2024. The company attributed this growth primarily to increased sales of its products, particularly the newly launched Etorel® and Contiva®, alongside a resurgence in sales of its established product, ETUARY®.

Operating expenses for the third quarter also rose, totaling $23.6 million compared to $21.3 million in the prior year, driven by higher selling and marketing costs, which increased by 12% to $15.3 million. Research and development expenses decreased by 15% to $2.4 million, reflecting the completion of certain clinical trials. Despite the rise in operating expenses, Gyre reported a net income of $5.9 million for the quarter, more than doubling from $2.9 million in the previous year. For the nine-month period, net income was $11.2 million, down from $17.3 million in 2024, largely due to a significant decrease in the change in fair value of warrant liability.

In terms of strategic developments, Gyre Pharmaceuticals, a subsidiary of Gyre Therapeutics, successfully launched two new products: Contiva® in March 2025 and Etorel® in June 2025. The company also increased its indirect ownership in Gyre Pharmaceuticals from 65.2% to 69.7% through a capital contribution of $1.28 million. This move is expected to enhance Gyre's operational control and financial performance in the biopharmaceutical market.

Operationally, Gyre has seen a positive trend in customer engagement, with a notable increase in sales attributed to a shift in marketing focus towards ETUARY® in the third quarter. The company reported cash and cash equivalents of $40.4 million as of September 30, 2025, a significant increase from $11.8 million at the end of 2024. This liquidity position, combined with net cash provided by operating activities of $6.6 million, positions Gyre favorably for future growth and investment in its product pipeline.

Looking ahead, Gyre anticipates continued revenue growth driven by the expansion of its product offerings and market penetration. The company is preparing to initiate a Phase 2 clinical trial for Hydronidone, targeting MASH-associated liver fibrosis, in 2026, contingent upon regulatory feedback. Gyre's management believes that existing cash reserves and operational cash flows will be sufficient to fund its activities for at least the next 12 months, although they may seek additional capital to support future growth initiatives.